As the use of glucagon-like peptide 1 (GLP-1) receptor agonists becomes more widespread, some patients and physicians are exploring microdosing—taking doses lower than the recommended therapeutic amount—for various reasons. Microdosing is being used for weight maintenance, metabolic health improvements, anti-inflammatory and autoimmune benefits, fewer side effects, and lower costs.